Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT01970475. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the effectiveness and safety of ABP 501 against adalimumab (HUMIRA®) in adults with moderate to severe rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX).
Study identification
- NCT ID
- NCT01970475
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 526 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2013
- Primary completion
- Oct 31, 2014
- Completion
- Oct 31, 2014
- Last update posted
- Dec 12, 2016
2013 – 2014
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Victorville | California | 92395 | — |
| Research Site | Jupiter | Florida | 33458 | — |
| Research Site | Sandy Springs | Georgia | 30328 | — |
| Research Site | Lansing | Michigan | 48910 | — |
| Research Site | Middleburg Heights | Ohio | 44130 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
Recently updated Arthritis, Rheumatoid trials
Other public records listing Arthritis, Rheumatoid. Sorted by last update posted; newest first. Not a recommendation.
- NCT07412704: A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis Not yet recruiting
- NCT05961592: R-2487 in Patients With Rheumatoid Arthritis Recruiting
- NCT05038553: Chronic Pain in Rheumatoid Arthritis Active, not recruiting
- NCT07176390: A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) Recruiting
- NCT06016517: Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis Not yet recruiting
- NCT04594993: INFINITY™ With ADAPTIS™ Technology Study Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01970475, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2016 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01970475 live on ClinicalTrials.gov.